Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of Zynex stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $8.92, for a total value of $17,840.00. Following the completion of the transaction, the chief executive officer now directly owns 14,625,350 shares of the company’s stock, valued at $130,458,122. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total value of $17,260.00.

Zynex Stock Performance

Shares of NASDAQ:ZYXI opened at $8.76 on Monday. The stock has a market capitalization of $278.97 million, a P/E ratio of 58.40 and a beta of 0.53. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The business has a 50-day moving average price of $8.11 and a two-hundred day moving average price of $9.04.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The firm had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. Equities analysts predict that Zynex, Inc. will post 0.2 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. HC Wainwright lifted their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada cut their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Institutional Trading of Zynex

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its holdings in Zynex by 22.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock worth $1,179,000 after purchasing an additional 26,368 shares during the last quarter. Investment Partners Asset Management Inc. acquired a new position in shares of Zynex during the 3rd quarter worth about $96,000. Cim LLC grew its position in shares of Zynex by 6.1% during the 2nd quarter. Cim LLC now owns 43,581 shares of the company’s stock worth $406,000 after buying an additional 2,508 shares during the period. Millennium Management LLC grew its position in shares of Zynex by 66.5% during the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after buying an additional 118,615 shares during the period. Finally, Sei Investments Co. grew its position in shares of Zynex by 32.3% during the 2nd quarter. Sei Investments Co. now owns 21,717 shares of the company’s stock worth $202,000 after buying an additional 5,300 shares during the period. 29.68% of the stock is owned by institutional investors.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.